Zhengye Biotechnology Holding Limited
ZYBT
$6.70
-$2.79-29.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -3.22% | -2.45% | -21.37% | -22.56% | -31.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.22% | -2.45% | -21.37% | -22.56% | -31.86% |
| Cost of Revenue | 18.98% | 19.93% | -17.85% | -19.09% | -26.19% |
| Gross Profit | -23.27% | -22.66% | -23.93% | -25.08% | -36.28% |
| SG&A Expenses | 3.20% | 4.03% | -1.31% | -2.81% | -28.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.00% | 14.91% | -11.52% | -12.86% | -24.58% |
| Operating Income | -90.22% | -90.13% | -50.79% | -51.54% | -54.19% |
| Income Before Tax | -93.22% | -93.16% | -52.96% | -53.67% | -50.32% |
| Income Tax Expenses | -154.72% | -155.12% | -23.98% | -25.09% | -32.55% |
| Earnings from Continuing Operations | -79.50% | -79.34% | -56.89% | -57.54% | -53.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 79.37% | 79.17% | 57.37% | 57.99% | 53.26% |
| Net Income | -79.52% | -79.37% | -56.79% | -57.45% | -53.05% |
| EBIT | -90.22% | -90.13% | -50.79% | -51.54% | -54.19% |
| EBITDA | -47.79% | -47.37% | -38.47% | -39.40% | -37.94% |
| EPS Basic | -79.53% | -79.41% | -56.83% | -57.59% | -53.02% |
| Normalized Basic EPS | -96.75% | -96.75% | -51.46% | -52.61% | -50.20% |
| EPS Diluted | -79.53% | -79.41% | -56.83% | -57.59% | -53.02% |
| Normalized Diluted EPS | -96.75% | -96.75% | -51.46% | -52.61% | -50.20% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.96% | -0.96% | 0.97% | 0.97% | 4.51% |